Inge W. Rossum

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Changes in insight and outcome over the early course of first-episode psychosis. The OPTiMiSE trial.

Changes in insight and outcome over the early course of first-episode psychosis. The OPTiMiSE trial.

Journal: Schizophrenia research. Cognition

Published: December 10, 2025

Depressive symptomatology in the first-episode schizophrenia spectrum disorders OPTiMiSE trial: prevalence, correlates, symptom progression and outcomes.

Depressive symptomatology in the first-episode schizophrenia spectrum disorders OPTiMiSE trial: prevalence, correlates, symptom progression and outcomes.

Journal: Schizophrenia (Heidelberg, Germany)

Published: May 18, 2025

Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial.

Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial.

Journal: CNS drugs

Published: May 16, 2025

Premorbid functioning trajectories and the one-year course of cognitive performance in first-episode psychosis: a cluster analysis in PSYSCAN.

Premorbid functioning trajectories and the one-year course of cognitive performance in first-episode psychosis: a cluster analysis in PSYSCAN.

Journal: Schizophrenia research. Cognition

Published: May 12, 2025

Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.

Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.

Journal: Schizophrenia (Heidelberg, Germany)

Published: September 04, 2024

Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.

Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.

Journal: Schizophrenia bulletin

Published: March 07, 2024

A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort.

A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort.

Journal: Schizophrenia research

Published: December 21, 2022

Relationships between social withdrawal and facial emotion recognition in neuropsychiatric disorders.

Relationships between social withdrawal and facial emotion recognition in neuropsychiatric disorders.

Journal: Progress in neuro-psychopharmacology & biological psychiatry

Published: May 11, 2021

Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial.

Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial.

Journal: BMC psychiatry

Published: November 05, 2020

The effect of prednisolone on symptom severity in schizophrenia: A placebo-controlled, randomized controlled trial.

The effect of prednisolone on symptom severity in schizophrenia: A placebo-controlled, randomized controlled trial.

Journal: Schizophrenia research

Published: October 05, 2020

Effect of disease related biases on the subjective assessment of social functioning in Alzheimer's disease and schizophrenia patients.

Effect of disease related biases on the subjective assessment of social functioning in Alzheimer's disease and schizophrenia patients.

Journal: Journal of psychiatric research

Published: August 31, 2020

The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics.

The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics.

Journal: Focus (American Psychiatric Publishing)

Published: July 01, 2016

Showing 1-12 of 12

Last Updated: 09/26/2026